Received: 10 November 2020
Accepted: 28 February 2021
First Online: 16 March 2021
: Institutional Review Board approval and consent to participate was achieved (IRCCS Burlo Garofolo-03/2020).
: Not applicable.
: AR has received grant support and/or speaking or consultant fees from AbbVie, Angelini, Bristol-Myers Squibb, Novartis, Pfizer, Reckitt-Benkiser, Roche and Johnson & Johnson; MC, SDP, FZ, CB, LV, AM, RS, RC, GZ, MF, DM, AM, AC, RMD, MCM, FLT, AM, GS, AV, RC and AT do not have any conflict of interest to declare.